These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 25905719)

  • 1. Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function.
    DeVay RM; Yamamoto L; Shelton DL; Liang H
    PLoS One; 2015; 10(4):e0125127. PubMed ID: 25905719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.
    Butkinaree C; Canuel M; Essalmani R; Poirier S; Benjannet S; Asselin MC; Roubtsova A; Hamelin J; Marcinkiewicz J; Chamberland A; Guillemot J; Mayer G; Sisodia SS; Jacob Y; Prat A; Seidah NG
    J Biol Chem; 2015 Jul; 290(30):18609-20. PubMed ID: 26085104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2).
    DeVay RM; Shelton DL; Liang H
    J Biol Chem; 2013 Apr; 288(15):10805-18. PubMed ID: 23430252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo.
    Fu T; Guan Y; Xu J; Wang Y
    Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):883-889. PubMed ID: 28495363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
    Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
    FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification.
    Tveten K; Holla ØL; Cameron J; Strøm TB; Berge KE; Laerdahl JK; Leren TP
    Hum Mol Genet; 2012 Mar; 21(6):1402-9. PubMed ID: 22156580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).
    Canuel M; Sun X; Asselin MC; Paramithiotis E; Prat A; Seidah NG
    PLoS One; 2013; 8(5):e64145. PubMed ID: 23675525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorting an LDL receptor with bound PCSK9 to intracellular degradation.
    Leren TP
    Atherosclerosis; 2014 Nov; 237(1):76-81. PubMed ID: 25222343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH.
    Lo Surdo P; Bottomley MJ; Calzetta A; Settembre EC; Cirillo A; Pandit S; Ni YG; Hubbard B; Sitlani A; Carfí A
    EMBO Rep; 2011 Dec; 12(12):1300-5. PubMed ID: 22081141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.
    Nassoury N; Blasiole DA; Tebon Oler A; Benjannet S; Hamelin J; Poupon V; McPherson PS; Attie AD; Prat A; Seidah NG
    Traffic; 2007 Jun; 8(6):718-32. PubMed ID: 17461796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation.
    Zhang DW; Lagace TA; Garuti R; Zhao Z; McDonald M; Horton JD; Cohen JC; Hobbs HH
    J Biol Chem; 2007 Jun; 282(25):18602-18612. PubMed ID: 17452316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide.
    Shan L; Pang L; Zhang R; Murgolo NJ; Lan H; Hedrick JA
    Biochem Biophys Res Commun; 2008 Oct; 375(1):69-73. PubMed ID: 18675252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9).
    Wang Y; Ye J; Li J; Chen C; Huang J; Liu P; Huang H
    Cardiovasc Diabetol; 2016 Feb; 15():19. PubMed ID: 26833058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor.
    Zhang DW; Garuti R; Tang WJ; Cohen JC; Hobbs HH
    Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13045-50. PubMed ID: 18753623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
    Ferri N; Tibolla G; Pirillo A; Cipollone F; Mezzetti A; Pacia S; Corsini A; Catapano AL
    Atherosclerosis; 2012 Feb; 220(2):381-6. PubMed ID: 22176652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.
    Romagnuolo R; Scipione CA; Marcovina SM; Gemin M; Seidah NG; Boffa MB; Koschinsky ML
    PLoS One; 2017; 12(7):e0180869. PubMed ID: 28750079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain.
    Liu M; Wu G; Baysarowich J; Kavana M; Addona GH; Bierilo KK; Mudgett JS; Pavlovic G; Sitlani A; Renger JJ; Hubbard BK; Fisher TS; Zerbinatti CV
    J Lipid Res; 2010 Sep; 51(9):2611-8. PubMed ID: 20453200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.